Search bioRxiv⌕ Search

Biology subjects

Lohmann, F.

Publications and source records attributed to Lohmann, F..

3 recordsLinked to original sources

Breaking the Synthesis Barrier for AI-Designed DNA Libraries

Designing DNA libraries is a key challenge from drug design to protein engineering and synthetic biology. Modern generative models offer opportunities to navigate the design space and propose specific sequences predicted to be effective in-silico. Designing deterministic libraries of specific sequences is however limited by the cost of DNA synthesis - the synthesis barrier. In contrast, high-throughput multiplexed screening can measure the function of billions of biological sequences in parallel. Harnessing this technology requires the design of randomized libraries with specific design constraints to achieve low synthesis costs. In practice, such stochastic libraries are often chosen heuristically, sacrificing control for scale. Is there a way to bridge AI-based in-silico sequence design with high-throughput experimentation? In this work, we introduce Policy Gradients for Library Design (PGLD). PGLD uses a synthesis-aware parametrization of stochastic DNA libraries and optimizes them against a specified objective function. This allows for designing massive, controlled libraries without being limited by synthesis costs. We show how PGLD enables lab-in-the-loop design of multi-round high-throughput experiments, and large-scale in-vitro DNA sampling from generative models. Finally, we use PGLD to design a library of ~ 106 unique sequences which is synthesized at a cost of ~ 700 USD to explore the mutation space of a broadly neutralizing influenza antibody.

bioengineering↗

CanSig: Discovering de novo shared transcriptional programs in single cancer cells

Single-cell RNA sequencing (scRNA-seq) facilitates the discovery of gene signatures that define cell states across patients, which could be used in patient stratification and drug discovery. However, the lack of standardization in computational methodologies to analyse these data impedes the reproducibility of signature detection. To address this, we developed CanSig, a comprehensive benchmarking tool that evaluates methods for identifying transcriptional signatures in cancer. CanSig integrates metrics for batch correction and biological signal conservation with a gene signature correlation metric to score according to rediscovery, cross-dataset reproducibility, and clinical relevance. We applied CanSig to ten methods and to ten scRNA-seq datasets from four human cancer types--glioblastoma, breast cancer, lung adenocarcinoma, and cutaneous squamous cell carcinoma-- representing 116 patients and 105,000 malignant cells. Our results identify BBKNN as a leading method. We showed that the signatures identified with these methods correlate with clinically relevant outcomes, including patient survival and lymph node metastasis. Thus, CanSig establishes a standardized framework for reproducible cancer transcriptomics analysis.

bioinformatics↗

Association of Ddx5/p68 protein with the upstream erythroid enhancer element (EHS1) of the Klf1 gene

EKLF/KLF1 is an essential transcription factor that plays a global role in erythroid transcriptional activation. Its own regulation is of interest, as it displays a highly restricted expression pattern, limited to erythroid cells and its progenitors. Here we use biochemical affinity purification to identify the Ddx5/p68 protein as an activator of KLF1 by virtue of its interaction with the erythroid-specific DNAse hypersensitive site upstream enhancer element (EHS1). We postulate that its range of interactions with other proteins known to interact with this element render it part of the enhanseosome complex critical for optimal expression of KLF1. These individual interactions provide quantitative contributions that, in sum, establish high level activity of the KLF1 promoter and suggest they can be selectively manipulated for clinical benefit.

molecular biology↗